|
Oral bisphosphonates Intravenous bisphosphonates
|
<0.001% (0% to 0.04%) 1.0% to 2.3% for 3-year administration
|
1.04 to 69 per 100,000 patient-years 0 to 12,222 per 100,000 patient-years
|
|
Anti-RANKL antibody Osteoporosis Cancer
|
1.3% to 3.2% for 3-year administration
|
0 to 30.2 per 100,000 patient-years 0 to 2,316 per 100,000 patient-years
|
|
Angiogenic inhibitors
|
0.3% to 0.4%
|
|
Anti-sclerostin antibody
|
Unknown
|
Unknown
|
|
Anti-TNFα antibody
|
|
Anti-CD20 antibody
|
|
Other monoclonal antibodies
|
|
Tyrosine kinase inhibitors
|
|
mTOR inhibitors
|
